Dendreon Set To Ship Provenge Within A Week
This article was originally published in The Pink Sheet Daily
Demand expected to exceed supply as company builds manufacturing capacity.
You may also be interested in...
The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.
The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.
The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.